Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics

New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials

CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) – Vyant Bio, Inc. (“Vyant” or the “Company”)  (Nasdaq: VYNT), an emerging leader in novel drug discovery techniques, announces a collaboration that  will seek to de-risk the development of small protein therapeutics. In partnership with Ordaōs Bio  (“Ordaōs”) and Cellaria, Inc. (“Cellaria”), the Company is unveiling a model for rapid iteration of  therapeutic design using artificial intelligence and in vitro ‘avatar clinical trials’ that will enable the design,  development, and testing of potential therapeutics on specific patient populations, during preclinical  development. The goal is to provide an early detection system of a drug’s efficacy in different patient  cohorts, prior to clinical trials.  

The collaboration capitalizes on the unique capabilities of each company to design, manufacture, and test  small-protein therapeutics that target multiple biomarkers derived from whole genome sequencing of  patient populations. Using proprietary AI, Ordaōs will generate in silico protein sequences, designed to  bind specific disease targets, and will serve as a blueprint for the collaborative team’s experts in in vitro and in vivo preclinical drug discovery, to produce the protein and rapidly iterate the structure using a  highly efficient expression system. Using Cellaria’s Patient Specific Cell Model Cohorts, the purified protein  will be critically evaluated for target binding and further optimized to improve performance across an  array of disease-specific genetic biomarker expressing cells. Once fully optimized by the team, Vyant Bio’s  objective will be to deliver regulatory readiness and a maximally de-risked drug candidate. The combined  solution will provide data and human-based insights not usually available until after a costly clinical trial. 

“Vyant Bio is committed to transforming the way that drugs are discovered by quickly adapting to exciting  new technologies and combining capabilities in ways that leverage their strengths,” stated Jay Roberts,  CEO of Vyant Bio. “Our collaboration with Ordaōs and Cellaria allows us all to work together to design and  develop superior therapeutics and position them to be as successful as possible before they get into the  clinic.” 

Cellaria Inc. uses cell biology in novel ways to provide insights into how a therapeutic may perform in  specific patient populations, prior to clinical trials. In this collaboration, Cellaria provides the means for  scientists to test how a drug will perform in a range of patient cohorts. The Cellaria in vitro and 3-D Models of tumor and metastatic niches are directly linked to a patient’s disease state and enable multiple  parametric deep data sets in genomics, proteomics, and combinatorial analysis.  

“Working with the Ordaōs and Vyant Bio teams has been incredibly important for us. Seeing the wealth  of patient data and cells used so seamlessly to inform and guide the design of a therapeutic is highly  rewarding,” stated David Deems, President and Founder of Cellaria Inc. “We are developing a repeatable  process that leverages well defined patient cohorts to learn as much as possible prior to embarking on a  clinical trial.” 

Ordaōs uses generative AI technology to accelerate the mini protein drug discovery and development  process. In this collaboration, Ordaōs provides a pipeline of digitally optimized therapeutics for further  development. The company was founded by David Longo, a Stanford and Harvard-trained AI and biotech  scientist, and Ulo Palm, MD, PhD, a 30-year veteran of clinical drug discovery and development at Allergan,  Novartis, and Schering Plough. 

“We are very excited about working with Vyant Bio and Cellaria to further our vision for transforming the  way we bring therapeutics to patients. At Ordaōs, we believe that designing, rather than discovering,  drugs is now possible with AI and will allow us to think bigger when we envision the impact we can have  on people’s lives.” said David Longo, CEO of Ordaōs. 

Ülo Palm, Ordaōs’ Chief Medical Officer, added that “the ultimate goal is to use modern AI to design the  next generation of highly effective and safe biologics for treating cancer and inflammatory diseases  thereby creating transformative treatment options for potentially millions of patients worldwide. We  expect that this new approach will significantly accelerate drug R&D overall and get the new drugs to  patients much faster than with the traditional drug development approach. Patients who suffer from  chronic and life-threatening diseases cannot wait. That is why this new collaboration is so important.” 

The three companies will continue to refine their strategies for drug design and development through a  series of projects targeting cancer, pancreatic, and autoimmune disorders. As the project evolves, the  therapeutic de-risking strategy will further incorporate the human-based biology and analytical software  of StemoniX, a wholly owned subsidiary of Vyant Bio. 

About Vyant Bio, Inc. 

Vyant Bio, Inc. (“Vyant Bio”) is emerging as an advanced biotechnology drug discovery company. With  capabilities in data, science (both biology and chemistry), engineering, and regulatory, we are rapidly  identifying small and large molecule therapeutics and derisking decision making through multiple in silico,  in vitro, and in vivo modalities. Leveraging these modalities, Vyant Bio is able to capitalize on repurposed  and novel compounds and then partner with others to further develop and commercialize valuable  therapeutics and new treatments for patients. Vyant Bio operates two wholly-owned subsidiaries,  StemoniX and vivoPharm and is empowering the discovery of new medicines through the convergence of  novel human biology and software technologies. 


StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate,  and consistent, these human models enable scientists to conduct research quickly and economically with  improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations,  StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom  human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC  technologies and data science, StemoniX is helping global institutions bring the most promising medicines  to patients. 

vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early  stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers.  vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies.  vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound  libraries, and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for  Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation  of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. 

About Ordaōs Bio 

Ordaōs employs a powerful proprietary AI engine and biological expertise to allow researchers to see  critical patterns and relationships in their data, unlocking previously unattainable and actionable insights  to design—rather than discover—novel therapeutic molecules. This will enable Ordaōs to accelerate  medical research, design complex therapeutic candidates and predict the outcomes of clinical trials. 

About Cellaria , Inc. 

Cellaria identifies disruptive ways to develop new in vitro and 3-D Models of tumors and metastatic niches  that are more directly linked to the patient’s disease state and enable multiple parametric deep data sets  in genomics, proteomics, and combinatorial analysis. Their capabilities include drug compound testing,  enrollment, and collection of patient specimens for model development, defining and monitoring clinically  relevant characteristics for each clinical disease category and across patient cohorts. This approach  provides more in-depth insight into the heterogeneity of patient characteristics in a disease category and  provides information about the stability and utility of the patient-specific model over time. 

For more information, please visit www.vyantbio.com; www.ordaos.bio and www.cellariainc.com. Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities  Litigation Reform Act of 1995. All statements pertaining to Vyant Bio Inc.’s (formerly Cancer Genetics, Inc.)  expectations regarding future financial and/or operating results, and potential for our services, future  revenues or growth, or the potential for future collaborations and strategic transactions in this press  release constitute forward-looking statements. 

Any statements that are not historical fact (including, but not limited to, statements that contain words  such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to  be forward-looking statements. Forward-looking statements involve risks and uncertainties, including,  without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve 

profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid  cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs,  realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant  Bio, Inc.’s Form 10-K for the year ended December 31, 2020, along with other filings with the Securities  and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio,  Inc. disclaims any obligation to update these forward-looking statements. 

Vyant Bio Investor Contact 

Jennifer K. Zimmons. Ph.D. 

Investor Relations  

Zimmons International Communications, Inc.  

Email: jzimmons@zimmonsic.com 

Phone: +1.917.214.3514